chrisvoncsefalvay/vaers-outcomes huggingface dataset:
(injection site)warm/now came back; (injection site)itchy; (injection site)hard; (injection site)red; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH ((injection site)warm/now came back), VACCINATION SITE PRURITUS ((injection site)itchy), VACCINATION SITE INDURATION ((injection site)hard) and VACCINATION SITE ERYTHEMA ((injection site)red) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH ((injection site)warm/now came back), VACCINATION SITE PRURITUS ((injection site)itchy), VACCINATION SITE INDURATION ((injection site)hard) and VACCINATION SITE ERYTHEMA ((injection site)red). At the time of the report, VACCINATION SITE WARMTH ((injection site)warm/now came back), VACCINATION SITE PRURITUS ((injection site)itchy), VACCINATION SITE INDURATION ((injection site)hard) and VACCINATION SITE ERYTHEMA ((injection site)red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
I started feeling pain in my arm and shoulder, but I didn't pay much attention to it. The next day, the area above my breast was hurting and tight. My husband took me to a healthcare facility and they took xrays and blood. They wanted to admit me, but I didn't want to stay. They gave me Tramadol for pain and told me to relax when I got home and to see my PCP. I was eventually able to get in about a week later and he did an ultrasound of my heart, an EKG and last week I took a stress test--which was abnormal and I have to go get my results today. I feel a lot better, but I still have pain in my chest area occasionally.
DELIRIOUS, HOT ARM, FATIGUE, DISORIENTED, TROUBLE GETTING TO THE BATHROOM, HEADACHE, TEMPERATURE, JOINT PAIN
Rash on chest and upper arms started next day - not itchy - raised bumpy. Also pain between shoulder blades on right hand side started on 4/09/18 and subsiding with naproxen.
pt recvd vax & started screaming & crying high pitched scream, gave APAP; head twitching to side, grunting noise x2; to MD, to hosp via amb ran tests, "no neuro damage" MD said rxn to pertussis;
Symptoms experienced were: scratchy throat, nausea, numbness to hands and feet and difficulty breathing.   Patient was seen in ED where Epi Pen was given and a few other treatments.
Signs and symptoms started around 1700hrs which included: body aches, chills, fever, and pain in the arm.  Signs and symptoms resolved the following morning (1/1/21) 0800hrs.
chills; low grade fever; This case was reported by a consumer via call center representative and described the occurrence of chills in a 54-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 1st August 2019, the patient received the 2nd dose of Shingrix. On 1st August 2019, less than a day after receiving Shingrix, the patient experienced chills and fever. On 2nd August 2019, the outcome of the chills and fever were recovered/resolved.   It was unknown if the reporter considered the chills and fever to be related to Shingrix.  Additional information was provided as follows: The case was reported by the wife of the patient. The age at the vaccination was not reported. The patient experienced low grade fever and chills. The reporter consented to follow up. Limited information was provided of the patient. This case linked with US2020075686 and US2020075693, reported by same reporter.
Pt had MMRV vaccine on 7-9-07. On 7/18/07 pt started running a fever of 103.4 and a rash. By 7-20-07 the rash had spread all over her body, she had matty eyes and cold symptoms. Her temp was now down to 100.4. The physician felt the rash was from the vaccine
This report described the occurrence of joint pain and swelling in a forty year old male patient who received Lyme disease vaccine recombinant for prophylaxis. This report was received as part of litigation proceedings. Medical records were subsequently provided. The patient received an injection of Lymerix on 6/17/00 according to the client. On 9/3/03, the patient's attorney alleged that the patient suffered joint pain and swelling within one week of vaccination according to the client. Treatment and outcomes of the alleged events were not reported. The following information was received via medical records. Medical history included lowe back pain for years. On 8/14/00, the patient presented with back pain and described being totally out of joint. On 2/14/03, the patient presented for orthopedic evaluation with complaints of right shoulder pain that began in approximately August 2002 following manual labor. X-rays revealed degenerative changes at the acromioclavicular joint with mild osteolysis at the distal clavicle. At that time, he was diagnosed with work-related shoulder pain, shoulder region impingement syndrome, and localized osteoarthritis, shoulder-acromioclavicular joint. He also complained of acute right neck pain which he felt was related to problems stemming from the unopposed action of the left upper trapezius impingement and atrophy of the right shoulder girdle, and reported inability to lift his arm without pain. Treatment included physical therapy. On 8/28/03, the patient underwent arthroscopy of the right shoulder including arthroscopic subacromial decompression and right distal clavulectomy for treatment of right shoulder impingement syndrome and acromioclavicular joint pain. Post operative diagnosis included right shoulder impingement syndrome and degenerative joint disease of the right acromioclavicular joint. Treatment included Tylenol+ codeine. Following the reported onset of joint pain and swelling, the patient experienced back and neck pain attributed to exertion, a disc bulge and lumbosacral strain while lifting with left leg/foot paresthesia. On 10/10/01, the patient reported that he bent over at work and his back went out. These were not reported as adverse events due to vaccine administration, but were found during the course of review of the patient's medical records. Therefore, they are not listed as adverse events. The most recent information received on 12/8/03 did not provide information about the outcome of joint pain and joint swelling.
This spontaneous report as received from Nursing Services refers to a patient of unknown age. On an unknown date the patient was vaccinated with an improperly stored vaccine of M-M-R II (lot # J002502, expired date 28-FEB-2015). The original reporter is unknown. Additional information has been requested.
lymphadenopathy; This is a spontaneous report received from contactable reporter(s) (Physician). The reporter is the patient.  A male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: LYMPHADENOPATHY (non-serious), outcome "recovered".  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. There was no information about patient's concomitant medications, pertinent medical history, drug reactions and allergies provided. On 28-JUL-2015, the patient was vaccinated with an improperly stored dose of GARDASIL 9 (lot# K026242, expiration date 28-JAN-2017, dose, route and site of administration were not reported). The vaccine was exposed to temperatures outside of the recommended range. No adverse experiences were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Information has been received on 15-FEB-2019 from a lawyer regarding a case in litigation concerning a 75 year old female patient. The patient's medical history, concurrent conditions and concomitant medication use were not provided. The patient was prescribed the ZOSTAVAX vaccine by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. In 2014 the patient was administered the ZOSTAVAX vaccine by healthcare provider (lot# and route unknown). In March 2017, the patient was treated by a physician for shingles as a result of vaccination with ZOSTAVAX.  On 17-APR-2018 the patient died. The cause of death was not provided. It is unknown if an autopsy was performed. The patient claims damages as a result of: injury to themselves, injury to the person represented; wrongful death; survivorship action, loss of services; economic losses. Upon internal review death was considered medically significant. Additional information has been requested.; Reported Cause(s) of Death: died.
This spontaneous report was received from a healthcare worker and refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' pertinent medical history, drug reactions, allergies, or concomitant therapies was provided. On unknown dates, the patients were vaccinated with improperly stored doses of VARIVAX (lot # M004328, expiration date 26-JAN-2018, exact doses and route of administration were not reported). The reason of the call was temperature alarm received via Digital Data Logger. It was reported that the vaccines were exposed to temperature of 9.6 Celsius degrees for 1 hour before administration to the patients. No previous temperature excursion was reported. No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Possible reaction to Varicella injection. Site of injection is red, hard to the touch, warm to the touch, itchy and redness is spreading.
Positional vertigo (BPPV), major episodes on following dates: 6/1/21, 8/24/21, 11/2/21, 11/27/21, 11/28/21, 12/4/21, 12/7/21.  Symptoms/signs/time course:  Vertigo (perceive objects in room moving, tipping sideways or downward), nausea, vomiting, lightheaded, unbalanced and unsteady trying to walk to bathroom; vertigo symptoms last 30-60 minutes; after vertigo stops, I still feel not OK normal, inside my head feels not normal, etc. ; the total episodes from initial vertigo to finally feeling OK lasts 2-3+ hours before it's over. Epley maneuver by doctor  not done during an episode, only after going to clinic.
01/21/2016 The day following vaccination the patient stated that she just didn't feel herself. 01/22/2016 Two days following vaccination the patient reported she woke up at 4:00 AM with major pain the back, the right shoulder, right arm and with pain also shooting down the right arm that was sharp and nagging. The pain was so bad her husband took her to the ER between 5-6 am that morning thinking that she was having a heart attack. All tests that morning came back negative. She has tried massage therapy which seemed to help some. But as of 2/4/2016, with a little improvement she is not back to her normal self yet. She is scheduled to see pain management physician next week.
pt recv vax 31OCT96 & 7NOV96 pt devel chickenpox consisting of mild papulovesicular rash/dermatitis w/less than 50 lesions on forehead, scalp & chest;pt was also noted that pt had positive exposure to children in day school w/chickenpox;
Apprx. 1 month following vaccine- thighs, upper arms, lower buttocks hurt. Comes and goes.
On Monday 11-30-15 pt received Tdap vaccine on right arm. On Tuesday 12-1-15 pt noticed right upper arm swelling, soreness and redness, and warm to touch. Pt came to walk-in clinic to see doctor. Prescribed antibiotics and was told to use cool compresses to (R) arm.
Headache, muscle pain, chills, fever, fatigue sweaty palm, sweaty feet, soreness at the injection site
Lump in the arm.  Steadily growing to around 5 inches long.  Painful. Stiffness in joint. Lethargy.
She had requested the Pfizer vaccine to receive her second dose. Pharmacist counseled her and advised her to switch to a different vaccine despite her reaction to the first vaccine. Pharmacist also asked if she had spoken with her doctor and she said yes, she can proceed to get the Pfizer vaccine. She insisted on getting the Pfizer vaccine as her second dose despite pharmacist consultation and pharmacist had an Epipen on hand to administer. She is aware that she has to wait 30 minutes after receiving the vaccine. About 15 minutes  later, she had difficulty swallowing and requested an Epipen be administered. Pharmacist called emergency and then proceeded to give her the Epipen while on the phone with dispatch until paramedics arrived to take her to the hospital.  She was awake and conscious the whole time, sitting in the chair. The pharmacist after the shot, checked in with her every 5 minutes to see if she was okay.
Potential AE due to doses administered from vials that may have been compromised; Vaccines were stored in an unapproved freezer/some of the freezers there was a temperature excursion; Administered vaccine from vials that may have been compromised; This spontaneous case was reported by a pharmacist and describes the occurrence of IMMUNISATION REACTION (Potential AE due to doses administered from vials that may have been compromised), PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccines were stored in an unapproved freezer/some of the freezers there was a temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine from vials that may have been compromised) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (Potential AE due to doses administered from vials that may have been compromised), PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccines were stored in an unapproved freezer/some of the freezers there was a temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine from vials that may have been compromised). At the time of the report, IMMUNISATION REACTION (Potential AE due to doses administered from vials that may have been compromised), PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccines were stored in an unapproved freezer/some of the freezers there was a temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine from vials that may have been compromised) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided.  The beyond use dates of the vaccine was reported as 01-Dec-2021 to 15-Dec-2021.  The reporter reported that they had a group of 13 pharmacies that had administered the Moderna vaccine. Their digital data loggers and freezers expired before they were re-calibrated. They were aware that in some of the freezers there was a temperature excursion that their data logs showed.   They wanted to reach out to see if the vaccines had been compromised. The vaccines had never reached a temperature that was considered outside of frozen recommended range. The data loggers had laps where they were not considered calibrated, so they had paper logs to monitor those temperatures.   The reporter asked whether they need to take any action in relation to the doses administered since the vaccines were stored in an unapproved freezer without a digital data logger. This was in several different freezers and the vial temperatures never went out of range when they were using the paper log.  No treatment information was provided.
This was the 2nd dose of the 2-dose Pfizer BioNTech COVID vaccines. The first dose was given on 8/11/2021, 16 days prior. The patient was notified of the error in vaccine dose spacing. There were no immediate or known adverse reactions.
Epstein-Barr levels were high; This spontaneous case was reported by a consumer and describes the occurrence of EPSTEIN-BARR VIRUS INFECTION (Epstein-Barr levels were high) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Epstein-Barr virus infection. Concomitant products included ACYCLOVIR [ACICLOVIR] for an unknown indication.   In August 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In August 2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In January 2022, the patient experienced EPSTEIN-BARR VIRUS INFECTION (Epstein-Barr levels were high). At the time of the report, EPSTEIN-BARR VIRUS INFECTION (Epstein-Barr levels were high) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Epstein-Barr virus antibody: high (High) count went high.         No Treatment information was provided.  The patient mentioned that prior and after primary series, Epstein-Barr virus lab work level was stable  for which was able to get the vaccine.
Arm pain  at injection site to a week. Muscle aches for about a week and a half to two weeks. Also had brain fog closer to three weeks. Hoped it would go away. Arm pain in left arm at injection site did not go away after 2nd injection see other report.
Entire arms hurts; Hot at the injection site; Hard at the injection site; Full body rash; Red at the injection site; Arm is really huge at the injection site, swollen; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Entire arms hurts), VACCINATION SITE WARMTH (Hot at the injection site), VACCINATION SITE INDURATION (Hard at the injection site), RASH (Full body rash) and VACCINATION SITE ERYTHEMA (Red at the injection site) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 17-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-May-2021, the patient experienced PAIN IN EXTREMITY (Entire arms hurts), VACCINATION SITE WARMTH (Hot at the injection site), VACCINATION SITE INDURATION (Hard at the injection site), RASH (Full body rash), VACCINATION SITE ERYTHEMA (Red at the injection site) and VACCINATION SITE SWELLING (Arm is really huge at the injection site, swollen). At the time of the report, PAIN IN EXTREMITY (Entire arms hurts), VACCINATION SITE WARMTH (Hot at the injection site), VACCINATION SITE INDURATION (Hard at the injection site), RASH (Full body rash), VACCINATION SITE ERYTHEMA (Red at the injection site) and VACCINATION SITE SWELLING (Arm is really huge at the injection site, swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided.  Treatment medications were unknown.
I was taken to emergency room following day for complications from vaccine, symptoms included shortness of breath, extreme joint pain.  I was given a course of steroids antiflamitories and was released next morning.   I have full report from Hospital ER. I can provide report if requested.
Patient was given a DTaP on 1-5-16 at 5:00PM. Mom reports swelling, redness w/splotchyness down past in his left knee on the night of 1-6-16. Mom brought patient to clinic 1-7-16 for evaluation. At this time, swelling and redness extended to left knee from upper thigh.
Vertigo; Fever; This spontaneous case was reported by an other health care professional and describes the occurrence of VERTIGO (Vertigo) and PYREXIA (Fever) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031L20A and 039K20A) for COVID-19 vaccination.     No medical history was provided by the reporter. The patient had no known drug allergies (NKDA) .  Concomitant products included ONE-A-DAY WOMEN'S for Nutritional supplement, CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY) for Seasonal allergy.   On 06-Jan-2021 at 3:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021 at 10:30 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Feb-2021 at 6:30 AM, the patient experienced VERTIGO (Vertigo) and PYREXIA (Fever). On 04-Feb-2021 at 10:30 AM, VERTIGO (Vertigo) and PYREXIA (Fever) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided by the reporter.   This case was linked to MOD-2021-008284 (Patient Link).   Reporter did not allow further contact
12/23/2021 pt presents to ED with weakness and history of passing out, positive COVID test ; on 12/16/21, pt was found to be positive for COVID (asymptomatic) when in Hospital for urinary retention, foley catheter placed; in ED pt found to have hyponatremia and UTI; given ABX, O2 supplementation, decadron, remdesivir, albuterol; AHRF secondary to COVID 19 PNA; DNR/DNI; transferred to comfort care; pt passed away in the hospital; DC and med records sent to info@vaers.org per VAERS request
Eight weeks after the second dose of the vaccine I got the Shingles. I had a rash on my left hip that wrapped around my body. It was painful but not as bad as I thought it might get. I was given Antiviral medication right away when I called my doctor. The rash lasted about two weeks but I felt fatigues for a month. I had the Chicken Pox as a child.
Raised, red, warm to tough circular area at injection site about 3 inches in diameter. Patient provider placed patient on antibiotics for cellulitis.